Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BeOne Pharmaceutical
Beijing, Beijing, China
- Ownership
- Private
- Development stage
- Other
01
Overview
BeOne Pharmaceutical is a clinical-stage biopharmaceutical company based in Beijing, China, focused on the discovery and development of innovative small molecule therapeutics for oncology. The company's lead programs target key mechanisms in DNA damage response (DDR) and tumor immunology. Its primary assets include BO-001, a selective USP1 inhibitor for homologous recombination deficiency (HRD) positive tumors, and BO-006, an HPK1 inhibitor designed to enhance anti-tumor immune responses. BeOne Pharmaceutical aims to address significant unmet medical needs in cancer treatment through precision medicine and novel drug design.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on BeOne Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BeOne Pharmaceutical.